Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: A pharmacokinetic and food effect study

Clinical Cancer Research

Volumn 15, Issue 11, 2009, Pages 3866-3871

  Ricart, Alejandro D ^a   Sarantopoulos, John ^a   Calvo, Emiliano ^a   Chu, Quincy S ^a   Greene, Douglas ^b   Nathan, Faith E ^b   Petrone, Michael E ^b   Tolcher, Anthony W ^a   Papadopoulos, Kyriakos P ^a,c  

^a CTRC Institute for Drug Development   (United States)

^b GPC Biotech Inc   (United States)

^c South Texas Accelerated Research Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SATRAPLATIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ANUS CANCER; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD TOXICITY; BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FOOD; FOOD DRUG INTERACTION; HUMAN; LEIOMYOSARCOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MERKEL CELL TUMOR; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; OVARY CARCINOMA; PAROTID GLAND CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ABDOMINAL PAIN; ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; EATING; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; VOMITING;

EID: 66649115071     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2373     Document Type: Article

References (30)

1. Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999;83:866-869
2. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003;23:460-464 (Pubitemid 37176691)
3. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003;30:5-13. (Pubitemid 37259547)
4. Rybak LP. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 2007;15:364-369 (Pubitemid 47373985)
5. Rose WC, Crosswell AR, Schurig JE, Casazza AM. Preclinical antitumor activity of orally administered platinum (IV) complexes. Cancer Chemother Pharmacol 1993;32:197-203. (Pubitemid 23146812)
6. Mellish KJ, Kelland LR, Harrap KR. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 1993;68:240-250
7. Ormerod MG, Orr RM, O'Neill CF, et al. The cytotoxic action of four ammine/amine platinum (IV) dicarboxylates: a flow cytometric study. Br J Cancer 1996;74:1935-1943. (Pubitemid 27007138)
8. Kelland LR, Abel G, McKeage MJ, et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 1993;53:2581-2586 (Pubitemid 23168026)
9. Sharp SY, Rogers PM, Kelland LR. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Clin Cancer Res 1995;1:981-989
10. O'Neill CF, Koberle B, Masters JR, Kelland LR. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Br J Cancer 1999;81:1294-1303
11. Kelland LR. An update on satraplatin: the first orally available platinum anticancer drug. Expert Opin Investig Drugs 2000;9:1373-1382 (Pubitemid 30342621)
12. Fokkema E, Groen HJ, Helder MN, de Vries EG, Meijer C. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. Biochem Pharmacol 2002;63:1989-1996 (Pubitemid 34687040)
13. McKeage MJ, Mistry P, Ward J, et al. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 1995;36:451-458
14. Beale P, Raynaud F, Hanwell J, et al. Phase I study of oral JM216 given twice daily. Cancer Chemother Pharmacol 1998;42:142-148 (Pubitemid 28267295)
15. McKeage MJ, Raynaud F, Ward J, et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997;15:2691-2700 (Pubitemid 27289902)
16. Kurata T, Tamura T, Sasaki Y, et al. Pharmacokinetic and pharmacodynamic analysis of bisacetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study. Jpn J Clin Oncol 2000;30:377-384
17. Fokkema E, de Vries EG, Meijer S, Groen HJ. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients. Cancer Chemother Pharmacol 2000;45:89-92. (Pubitemid 30099722)
18. Sternberg CN, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005;68:2-9. (Pubitemid 40675002)
19. Latif T, Wood L, Connell C, et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily - 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs 2005;23:79-84.
20. Judson I, Cerny T, Epelbaum R, et al. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol 1997;8:604-606 (Pubitemid 127746494)
21. McKeage MJ, Boxall FE, Jones M, Harrap KR. Lack of neurotoxicity of oral bisacetatoammine-dichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat. Cancer Res 1994;54:629-631 (Pubitemid 24979998)
22. Fokkema E, Groen HJ, Bauer J, Uges DR, Weil C, Smith IE. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol 1999;17:3822-3827
23. Anonymous. A randomized phase II study of satraplatin (JM-216) or standard platinum therapy in patients with late relapses of epithelial ovarian cancer (CA 142-006). Bristol-Myers Squibb Report 1998; Accession No.910068667.
24. Sternberg CN, Petrylak DP, Witjes F, et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial [abstract 5019]. J Clin Oncol 2007;25.
25. George CM, Haraf DJ, Mauer AM, et al. A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. Invest New Drugs 2001;19:303-310 (Pubitemid 32782970)
26. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-584
27. Food and Drug Administration. Food-effect bioavailability and fed bioequivalence studies. Rockville (MD): 2002.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al. European Organization for Research and Treatment of CancerNational Cancer Institute of the United StatesNational Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216
29. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-3467 (Pubitemid 29517916)
30. Sartor AO, Petrylak DP, Witjes JA, et al. Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial [abstract 5003]. J Clin Oncol 2008;26.